Belgian biotech retains its top position despite the turbulent times
Belgium’s biotech sector defied global headwinds in 2024, delivering growth and key milestones. The latest analysis compiled by KBC Securities and PMV for Biovia confirms Belgium’s leadership in European health innovation. But staying on top will demand continued resilience and strategic focus.
Over the past five years, Belgium has steadily built a reputation as one of Europe’s premier biotech hubs. Strong public-private partnerships, an open innovation culture, and world-class scientific institutions have fueled growth across the sector. The ecosystem’s strength has been evident in record-setting public market valuations, successful M&A activity, and a steady flow of venture capital into promising startups.